26 July 2025 in Nature Communications
Drug-target interaction (DTI) prediction is a crucial component of drug discovery. Recent deep learning methods show great potential in this field but also encounter substantial challenges. These include generating reliable confidence estimates for predictions, enhancing robustness when handling novel, unseen DTIs, and mitigating the tendency toward overconfident and incorrect predictions. To solve these problems, we propose EviDTI, a novel approach utilizing evidential deep learning (EDL) for uncertainty quantification in neural network-based DTI prediction. EviDTI integrates multiple data dimensions, including drug 2D topological graphs and 3D spatial structures, and target sequence features. Through EDL, EviDTI provides uncertainty estimates for its predictions. Experimental results on three benchmark datasets demonstrate the competitiveness of EviDTI against 11 baseline models. In addition, our study shows that EviDTI can calibrate prediction errors. More importantly, well-calibrated uncertainty information enhances the efficiency of drug discovery by prioritizing DTIs with higher confident predictions for experimental validation. In a case study focused on tyrosine kinase modulators, uncertainty-guided predictions identify novel potential modulators targeting tyrosine kinase FAK and FLT3. These results underscore the potential of evidential deep learning as a robust tool for uncertainty quantification in DTI prediction and its broader implications for accelerating drug discovery.
8 November 2024 in Nature Machine Intelligence
Variational graph encoders effectively combine graph convolutional networks with variational autoencoders, and have been widely employed for biomedical graph-structured data. Lam and colleagues developed a framework based on the variational graph encoder, NYAN, to facilitate the prediction of molecular properties in computer-assisted drug design. In NYAN, the low-dimensional latent variables derived from the variational graph autoencoder are leveraged as a universal molecular representation, yielding remarkable performance and versatility throughout the drug discovery process. In this study we assess the reusability of NYAN and investigate its applicability within the context of specific chemical toxicity prediction. The prediction accuracy—based on NYAN latent representations and other popular molecular feature representations—is benchmarked across a broad spectrum of toxicity datasets, and the adaptation of NYAN latent representation to other surrogate models is also explored. NYAN, equipped with common surrogate models, shows competitive or better performance in toxicity prediction compared with other state-of-the-art molecular property prediction methods. We also devise a multi-task learning strategy with feature enhancement and consensus inference by leveraging the low dimensionality and feature diversity of NYAN latent space, further boosting the multi-endpoint acute toxicity estimation. The analysis delves into the adaptability of the generic graph variational model, showcasing its aptitude for tailored tasks within the realm of drug discovery.
13 November 2024 in Research Square
Drug-target interaction (DTI) prediction is a crucial component of drug discovery. Recent deep learning methods show great potential in this field but also encounter substantial challenges. These include generating reliable confidence estimates for predictions, enhancing robustness when handling novel, unseen DTIs, and mitigating the tendency toward overconfident and incorrect predictions. To solve these problems, we propose EviDTI, a novel approach utilizing evidential deep learning (EDL) for uncertainty quantification in neural network-based DTI prediction. EviDTI integrates multiple data dimensions, including drug 2D topological graphs and 3D spatial structures, and target sequence features. Through EDL, EviDTI provides uncertainty estimates for its predictions. Experimental results on three benchmark datasets demonstrated the competitiveness of EviDTI against five state-of-the-art baseline models. In addition, our study shows that EviDTI can calibrate prediction errors. More importantly, well-calibrated uncertainty information enhanced the efficiency of drug discovery by prioritizing DTIs with higher confident predictions for experimental validation. In a case study focused on tyrosine kinase inhibitors (TKIs), uncertainty-guided predictions identified novel potential inhibitors targeting FAK and FLT3. These results underscore the potential of evidential deep learning as a robust tool for uncertainty quantification in DTI prediction and its broader implications for accelerating drug discovery.